Potential entry into high growth GLP-1 market of nearly $50 billion in 2024, projected value of $100 billion by 2029 BALTIMORE--(BUSINESS WIRE)-- TNF Pharmaceuticals, Inc. (TNFA) (“TNF” or the ...
“We’re witnessing a renaissance in cytokine targeting,” says Dr. Emily Rhodes, immunologist at the Stanford Institute for Translational Medicine. “And TNF-α is still the most contested—and the most ...
BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results